CannAssist (OTCQB: CNSC), the parent company of Xceptor Labs and developer of innovative CiBiDinol technology, was featured in an episode of The Bell2Bell Podcast, produced by InvestorBrandNetwork (“IBN”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. Bell2Bell’s latest podcast features Mark Palumbo, founder and CEO of CannAssist, as he discusses the company’s CiBiDinol technology. Palumbo noted that CannAssist’s platform, which was developed as a product of the company’s subsidiary, Xceptor Labs, is capable of improving the performance of CBD and a host of other oil-soluble active ingredients, including non-CBD cannabinoids, terpenes, essential oils and oil-soluble vitamins. He also discussed the company’s business model. “Xceptor Labs uses a B2B business model. We basically can generate a raw material and customize that raw material. We can sell it to other tech houses … and, of course, for the branded companies, we can do it in such a way that we can customize what they’re looking for and help them make the claims that they seek to make,” Palumbo said in the interview. “The other side of the business for us is B2C. We have a brand we call Xceptol. Once we were having the level of success we were with the performance of this product, we really wanted to get it to as many people as we could … to make sure that it was accessible and understandable.”
To view the full press release, visit https://ibn.fm/PszdI
About Cann+Assist International Corporation
CannAssist, the parent company of Xceptor Labs, produces and sells its CiBiDinol technology, formulated using a proprietary process developed by the company’s founder, Mark Palumbo. Research and development aimed at enhancing the bioavailability of oil-soluble molecules resulted in the company’s CiBiDinol technology. CiBiDinol is the driving force behind CannAssist’s Xceptol brand of consumable and topical products. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, Xceptol Pain Cream is a CBD product with industry defining reliability and compliance. CannAssist believes Xceptol represents the next step for CBD products. CBD is a non-psychoactive compound found in hemp. View the company’s products on RangeMe, an online platform that enables retail buyers to efficiently discover consumer-ready, innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights and services they need. For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.